Uptake and retention of the photosensitizer mono-l-asparthyl chlorine e6 in experimental malignant glioma

The objective of the study was to investigate the potential of mono-l-aspartyl chlorine e6 (NPe6), a water-soluble photosensitizer derived from chlorophyll, for use in photodynamic diagnosis (PDD) of malignant brain tumor. A C6 glioma cell line was transplanted in the SD rat brain to create a brain tumor model. Five days after transplantation, NPe6 was administrated via the tail vein at concentrations ranging from 1.25 to 10 mg/kg; then the skull was opened in the rat brain, the site of tumor transplant was irradiated with a diode laser beam at 664 nm, and the time-course intensity and distribution of emerging fluorescence were observed. Furthermore, the correlation between fluorescence distribution and histopathological findings was investigated in the removed brain. Fluorescence was observed in the site of brain tumor transplant from 5 min after injection, and stable fluorescence was recognized at the site until 4 h after administration. No differences were noted in fluorescence intensity at NPe6 doses of 2.5 mg/kg or more; therefore, it was possible to estimate the optimal dose range. Fluorescence distribution had a clear correlation with tumor cell density, and it was possible to capture the margin of tumor cell invasion with fluorescence. The photosensitizer NPe6 is capable of assessing tumor cell density in malignant glioma tissue in terms of differences in fluorescence intensity. The usefulness of PDD using 5-aminoleveulinic acid during surgery for malignant glioma has been recognized in recent years. The results of the present study suggested the potential of NPe6 as a promising photosensitizer for use in PDD for accurate grasp of the extent of removal during the course of malignant glioma surgery.

[1]  Hirofumi Kawabe,et al.  LOCALIZATION OF MONO‐L‐ASPARTYL CHLORIN e6 (NPe6) IN MOUSE TISSUES , 1987, Photochemistry and photobiology.

[2]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[3]  G. Moore,et al.  The clinical use of fluorescein in neurosurgery; the localization of brain tumors. , 1948, Journal of neurosurgery.

[4]  B. Wilson,et al.  Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. , 1996, Journal of clinical laser medicine & surgery.

[5]  M W Berns,et al.  Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. , 1988, Journal of the National Cancer Institute.

[6]  A H Kaye,et al.  Selective uptake of hematoporphyrin derivative into human cerebral glioma. , 1990, Neurosurgery.

[7]  S. Stylli,et al.  Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C J Gomer,et al.  Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1992, Cancer research.

[9]  C Rivano,et al.  Fast attempts at the photodynamic treatment of human gliomas. , 1980, Journal of neurosurgical sciences.

[10]  M W Berns,et al.  In vitro photosensitization I. Cellular uptake and subcellular localization of mono‐L‐aspartyl chlorin e6, chloro‐aluminum sulfonated phthalocyanine, and photofrin II , 1989, Lasers in surgery and medicine.

[11]  G Jori,et al.  Photodynamic therapy of malignant brain tumors: clinical results of, difficulties with, questions about, and future prospects for the neurosurgical applications. , 1988, Neurosurgery.

[12]  J E Kaufman,et al.  Photoradiation therapy for the treatment of malignant tumors. , 1978, Cancer research.

[13]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[14]  M W Berns,et al.  In vitro characterization of monoaspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy. , 1988, Journal of the National Cancer Institute.

[15]  D. Kessel INTERACTIONS BETWEEN N‐ASPARTYL CHLORIN E6, DETERGENT MICELLES AND PLASMA LIPOPROTEINS , 1995, Photochemistry and photobiology.

[16]  A. Zinsmeister,et al.  Mono‐L‐aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model , 1998, Cancer.

[17]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[18]  I. Ciric,et al.  Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal Tumors , 1998 .

[19]  A H Kaye,et al.  Photodynamic therapy of brain tumors. , 1995, Journal of clinical laser medicine & surgery.

[20]  T J Dougherty,et al.  PHOTOSENSITIZERS: THERAPY AND DETECTION OF MALIGNANT TUMORS , 1987, Photochemistry and photobiology.

[21]  T J Dougherty,et al.  DISTRIBUTION AND ELIMINATION OF PHOTOFRIN II IN MICE , 1989, Photochemistry and photobiology.

[22]  U. Muller-eberhard,et al.  Interaction of hemopexin, albumin and liver fatty acid‐binding protein with protoporphyrin , 1989, Hepatology.

[23]  H. Kato,et al.  Photodynamic Therapy with a Diode Laser for Implanted Fibrosarcoma in Mice Employing Mono‐L‐Aspartyl Chlorin E6 , 1996, Photochemistry and photobiology.

[24]  A H Kaye,et al.  Uptake and retention of hematoporphyrin derivative in an in vivo/in vitro model of cerebral glioma. , 1985, Neurosurgery.

[25]  H Stepp,et al.  Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. , 2000, Journal of neurosurgery.

[26]  D. Kessel,et al.  LIPOPROTEIN‐MEDIATED DISTRIBUTION OF N‐ASPARTYL CHLORIN‐E6 IN THE MOUSE , 1992, Photochemistry and photobiology.

[27]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[28]  A H Kaye,et al.  Photoradiation therapy and its potential in the management of neurological tumors. , 1988, Journal of neurosurgery.

[29]  D. Kessel,et al.  Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients. , 1997, Journal of photochemistry and photobiology. B, Biology.

[30]  T. Okunaka,et al.  Localization of experimental submucosal esophageal tumor in rabbits by using mono‐L‐aspartyl chlorin e6 and long‐wavelength photodynamic excitation , 2000, Lasers in surgery and medicine.

[31]  M W Berns,et al.  In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy. , 1987, Cancer research.

[32]  M W Berns,et al.  In vitro photosensitization II. An electron microscopy study of cellular destruction with mono‐L‐aspartyl chlorin e6 and photofrin II , 1989, Lasers in surgery and medicine.

[33]  C J Gomer,et al.  Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1990, Cancer research.